Eric J Nestler, MD, PhD
img_Eric J Nestler
PROFESSOR | Neuroscience
PROFESSOR | Pharmacological Sciences
PROFESSOR | Psychiatry
Are you a patient?
Research Topics
Addiction, Behavioral Health, Depression, Epigenetics, Molecular Biology, Neuroscience, Stress, Synapses, Synaptic Plasticity, Synaptogenesis
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Neuroscience [NEU]
Nestler Lab, Laboratory of Molecular Psychiatry

Specific Clinical/Research Interest: Molecular neurobiology of drug addiction and depression; transcriptional and epigenetic regulation in the brain.

Our research focuses on identifying the neurobiological basis of drug addiction and depression in rodent models. We study the molecular and cellular changes that occur in regions of the brain important for reward and motivation in response to chronic administration of a drug of abuse or chronic exposure to stress. We are particularly interested in long-lasting changes that are mediated via alterations in gene expression and chromatin remodeling. The result of the research will guide future efforts toward the development of more effective treatments for addiction and depression.

Current Team

For a complete list of publications, please visit Selected Publications.

For more, please visit the Nestler Lab.

MD, Yale University School of Medicine

PhD, Yale University

Internship, Psychiatry, McLean Hospital

Residency, Psychiatry, Yale University School of Medicine

Fellowship, Clinical Pharmacology, Yale University School of Medicine

Fellowship, Psychiatry, Yale University School of Medicine


Redelsheimer Distinguished Research Award, Society of Biological Psychiatry


Wilbur Cross Distinguished Alumnus Medal, Yale University


Paul Hoch Distinguished Service Award


Sarnat Prize, Institute of Medicine


American Academy of Arts and Science


Institute of Medicine (National Academy of Medicine)

FBI Cyber Series - Transcriptional and Epigenetic Mechanisms of Addiction by Eric Nestler, MD, PhD
Neurobiology of Drug Addiction Part 2
Neurobiology of Drug Addiction Part 1

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Nestler during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Company Founder:

  • PsychoGenics, Inc.


  • Society of Biological Psychiatry
  • PsychoGenics, Inc.
  • Biohaven Pharmaceuticals

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Berg Pharma (Berg Biosystems)
  • PsychoGenics, Inc.

Scientific Advisory Board:

  • Berg Pharma (Berg Biosystems)

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.